文献速递脑血管病神经重症与神经感染

后循环AIS取栓成功后动脉内阿替普酶溶栓:IAT-TOP随机临床试验

Intra-arterial Alteplase Thrombolysis After Successful Thrombectomy for AIS in the Posterior Circulation: The IAT-TOP Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2026-01-01

这项多中心随机对照试验纳入中国37家卒中中心的246例急性基底动脉闭塞患者,在血管内取栓成功再通后比较动脉内阿替普酶与对照组的疗效与安全性。

要点

  • 后循环取栓成功后辅助动脉内阿替普酶未改善90天功能独立。
  • 动脉内阿替普酶组90天死亡率和症状性颅内出血与对照组相似。
  • 该辅助治疗在本研究中显示安全但无功能获益。

核心结论

  • 急性基底动脉闭塞患者血管内取栓成功再通后,动脉内阿替普酶看似安全但未改善90天功能结局。

研究设计与样本

  • 多中心、前瞻性、随机、开放标签、盲法终点(PROBE设计)临床试验,在中国37家综合卒中中心开展。
  • 共纳入247例患者,1例因动脉内阿替普酶前基底动脉再闭塞被排除,最终246例纳入分析。
  • 246例中治疗组124例(50.4%),对照组122例(49.6%);中位年龄65.0岁(IQR 56.0-72.0),男性176例(71.5%)。
  • 纳入标准为成年急性基底动脉闭塞患者,最后已知良好时间24小时内,取栓成功后成功再通。

主要发现

  • 90天功能独立(mRS 0-2)在动脉内阿替普酶组为52例(41.9%),对照组为57例(46.7%)。
  • 90天死亡率在动脉内阿替普酶组为29.6%,对照组为27.0%。
  • 48小时内症状性颅内出血发生率在动脉内阿替普酶组为2.4%,对照组为2.5%。

关键数值与推荐

  • 干预方案:动脉内阿替普酶0.225 mg/kg,最大剂量22.5 mg,浓度1.0 mg/mL,15分钟内输注于小脑后下动脉起始部远端。

临床怎么用

  • 对于急性基底动脉闭塞取栓成功再通的患者,动脉内阿替普酶辅助治疗未显示功能获益,不应常规使用。
  • 该辅助治疗在本研究中未增加死亡或症状性颅内出血风险,但需结合个体情况谨慎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The impact of adjunctive intra-arterial alteplase after successful endovascular thrombectomy (EVT) in patients with acute ischemic stroke due to large-vessel occlusion (AIS-LVO) in the posterior circulation requires further investigation. OBJECTIVE: To assess the efficacy and safety of intra-arterial alteplase after successful EVT for AIS-LVO in the posterior circulation. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, prospective, randomized, open-label, blinded-end point (PROBE design) clinical trial. The study was conducted between September 5, 2023, and November 29, 2024, with the 3-month follow-up completed on February 18, 2025. The trial was conducted in 37 comprehensive stroke centers in China. Patients in China with acute basilar artery occlusion presenting within 24 hours of the time last known well were randomly assigned to the treatment group or control group. Eligible participants were adults who achieved successful recanalization after EVT. INTERVENTIONS: Eligible patients were randomly assigned to the intra-arterial alteplase group (0.225 mg/kg, maximum dose limit 22.5 mg infused at a concentration of 1.0 mg/mL within 15 minutes distal to the origin of posterior inferior cerebellar artery) or control group (no intra-arterial thrombolysis). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the proportion of patients achieving functional independence (modified Rankin Scale score of 0-2) at 90 days. The primary safety outcomes were mortality at 90 days and incidence of symptomatic intracranial hemorrhage within 48 hours. RESULTS: A total of 247 patients were enrolled, and 1 patient was excluded from the full analysis set due to basilar artery reocclusion before intra-arterial alteplase. The remaining 246 patients (median [IQR] age, 65.0 [56.0-72.0] years; 176 male [71.5%]) were included in this analysis, 124 (50.4%) in the treatment group and 122 (49.6%) in the control group. Among the patients recruited and followed up, functional independence at 90 days was achieved in 52 (41.9%) in the intra-arterial alteplase group and 57 (46.7%) in the control group (adjusted risk ratio, 0.93; 95% CI, 0.73-1.18; P = .55). Mortality at 90 days (29.6% vs 27.0%, respectively; adjusted hazard ratio, 1.07; 95% CI, 0.71-1.61; P = .75) and incidence of symptomatic intracranial hemorrhage (2.4% vs 2.5%, respectively; unadjusted risk ratio, 0.98; 95% CI, 0.20-4.74; P = .97) were similar across groups. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that in patients with posterior circulation stroke due to acute basilar artery occlusion, intra-arterial alteplase after successful endovascular recanalization appeared to be safe but was not associated with improvement of functional outcomes at 90 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05897554.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Chen W, Yang B, Bai X, et al. Intra-arterial Alteplase Thrombolysis After Successful Thrombectomy for AIS in the Posterior Circulation: The IAT-TOP Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42026933. doi:10.1001/jamaneurol.2026.1074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。